Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 2/20 | 0.58 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.58 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.58 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.58 |
| ▸ | SELP | P16109 | 1/20 | 0.52 |
| ▸ | CNR2 | P34972 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | FAAH | O00519 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | CNR1 | P21554 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8004528 | 0.97 | PRKCA (0.61) | PRKCAPRKCEPRKCQPRKCDSELP | |
| SCHEMBL24614919 | 0.90 | PRKCA (0.68) | PRKCAPRKCEPRKCQPRKCDSELP | |
| SCHEMBL26122535 | 0.90 | PRKCA (0.68) | PRKCAPRKCEPRKCQPRKCDSELP | |
| SCHEMBL27355138 | 0.90 | PRKCA (0.68) | PRKCAPRKCEPRKCQPRKCDSELP | |
| SCHEMBL9472418 | 0.90 | PRKCA (0.71) | PRKCAPRKCEPRKCQPRKCDSELP | |
| SCHEMBL9472428 | 0.90 | PRKCA (0.71) | PRKCAPRKCEPRKCQPRKCDSELP | |
| SCHEMBL9861357 | 0.90 | PRKCA (0.71) | PRKCAPRKCEPRKCQPRKCDSELP | |
| SCHEMBL9861368 | 0.90 | PRKCA (0.71) | PRKCAPRKCEPRKCQPRKCDSELP | |
| SCHEMBL8017492 | 0.88 | PRKCA (0.60) | PRKCAPRKCEPRKCQPRKCDALDH1A1 | |
| SCHEMBL24615031 | 0.86 | PRKCA (0.70) | PRKCAPRKCEPRKCQPRKCDSELP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12024484-B2 | Lipid formulations for gene editing | VERVE THERAPEUTICS, INC. (US) | 2024-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12024484-B2 | Lipid formulations for gene editing | LIPA, LIPC, ABHD16A | PRKCA 1532/4885PRKCE 2129/4885PRKCQ 1274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.